1.Treatment result for lung cancer with brain metastasis
Mingchi TU ; Hanjue LUO ; Zhida MAO
Chinese Journal of Radiation Oncology 1992;0(01):-
Purpose: To report the treatment result for lung cancer with brain metastasis. Materials and Methods: 117 patients with brain metastases from lung cancers were treated by radiotherapy alone or surgery followed by radiotherapy from January, 1987 to December, 1993. Radiotherapy were given with the dose of 23~40Gy (whole brain irradiation) then followed with 15~24Gy booster. Results: The median survival period and one year survival rate were 9.5 months and 62.5% in surgery plus radiotherapy group and 5.7 months and 14.2% in radiotherapy alone group(P
2.Long-term results of prophylactic cranial irradiation for limited-stage small-cell lung cancer in complete remission
Kajia CAO ; Huiying HUANG ; Mingchi TU ; Guoying PAN
Chinese Journal of Radiation Oncology 1992;0(04):-
Objective To evaluate the effects of prophylactic cranial irradiation (PCI) on the survival and brain metastatic rates in patients with limited stage small cell lung cancer (SCLC) in complete remission. Methods Fifty one patients with limited stage SCLC in complete remission after chemoradiotherapy were randomly divided into prophylactic cranial irradiation (PCI) group (n=26) and control group (n=25). Patients in PCI group received irradiation to a dose of 25.2~30.6?Gy by 1.8~2.0?Gy per fraction. With the survival rates of the two groups analyzed by life table and compared by Log Rank test, the difference in cranial metastatic rates between the two groups were tested by ? 2 test. The patients' clinical features such as age, sex, effect of treatment before PCI were comparable between the two groups. Results The incidence of cranial metastasis was 3.8% in the PCI group as compared with 32.0% in the control group, with the difference significant (? 2=5.15, P= 0.02 ). The 1 , 3 , 5 year survival rates were 84.6%, 42.3%, 34.6% in the PCI group and 72.0%, 32.0%, 24.0% in the control group, with no significant difference between the two groups (? 2=2.25, P=0.13). No serious complications were observed in patients who received PCI. Conclusion For patients with limited stage SCLC complete response after chemoradiotherapy, PCI can decrease the incidence of cranial metastasis and tends to improve the survival rate.